Senex Biotechnology. Inc. Email Format

Biotechnology ResearchSouth Carolina, United States2-10 Employees

Senex Biotechnology, Inc. is a small clinical-stage biotechnology company based in Columbia, South Carolina, focused on cancer biology. It seeks to prevent transcriptional reprogramming, the process by which cancer cells rewire gene expression to endure adversity, contributing to drug resistance and metastasis. Its lead effort targets CDK8/19 Mediator Kinase, a transcriptional regulator that is not essential for adult cells, with the goal of addressing drug resistance and metastatic progression in currently incurable prostate and breast cancers while avoiding unintended effects.

The lead clinical candidate, SNX631-6, is described as an orally available, selective inhibitor of CDK8/19 with strong potency and favorable pharmacokinetics demonstrated in preclinical studies. In preclinical models, SNX631-6 has been associated with limiting drug resistance in castration-resistant prostate cancer, reducing growth of bone-resident tumors and angiogenesis, and lowering expression of tumor-promoting genes.

Get verified Senex Biotechnology. Inc. emails free

Company overview Employee directory